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Abstract: Nonmyeloablative and reduced-intensity conditioning 
regimens followed by allogeneic hematopoietic cell transplantation 
(HCT) have been evaluated in patients with hematologic malignancies 
who were not considered candidates for conventional HCT because 
of age or medical comorbidities and in selected patients with meta-
static renal cell carcinoma. The regimens have relied more on graft-
versus-tumor effects than on chemoradiation therapy to facilitate 
engraftment and eradicate malignant cells. While nonmyeloablative 
HCT has been associated with reduced regimen-related toxicities 
and has been curative for a number of patients with hematologic 
malignancies, challenges have remained in regard to graft-versus-host 
disease, infections, and disease progression. In this article, we review 
data from a number of published phase I and II studies that describe 
the results of allogeneic HCT after nonmyeloablative conditioning.
Allogeneic hematopoietic cell transplantation (HCT) after a high-dose myeloablative conditioning regimen has been an eﬀ ective treatment for many patients with hematologic 
malignancies.1 Due to regimen-related toxicities, however, the use 
of ablative regimens has been restricted to younger and medically ﬁ t 
patients. Th is is unfortunate because the median age at diagnosis of 
patients with hematologic malignancies such as acute and chronic 
leukemias, lymphomas, myelodysplastic syndromes (MDS), and 
multiple myeloma (MM) ranges from 65 to 70 years.2 It has been 
recognized for some time, however, that the curative potential of 
allogeneic HCT can be ascribed not only to the eradication of 
malignant cells by high-dose chemotherapy and total body irra-
diation (TBI) but also to immune-mediated graft-versus-tumor 
eﬀ ects.3-5 Th ese observations led several investigators to explore the 
curative potential of donor lymphocyte infusions (DLI) in patients 
with hematologic malignancies who had relapsed after allogeneic 
HCT.6-8 Th e induction of durable complete remissions by DLI in 
a number of patients demonstrated that graft-versus-tumor eﬀ ects 
were capable of eradicating hematologic malignancies, even in the 
absence of chemotherapy.
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In an attempt to extend the use of allogeneic HCT 
to include older patients and those with comorbid con-
ditions, several groups of investigators have developed 
reduced-intensity9-12 or truly nonmyeloablative condition-
ing regimens,13-15 in which the burden of tumor eradica-
tion is shifted from high-dose chemoradiation therapy 
toward graft-versus-tumor eﬀ ects. 
Most of the reduced-intensity conditioning regimens 
do not meet the criteria of nonmyeloablative conditioning, 
which include: 1) no eradication of host hematopoiesis, 2) 
prompt hematologic recovery (<4 weeks) without HCT, 
and 3) presence of mixed chimerism (ie, coexistence of 
hematopoietic cells of host and donor origin) upon 
engraftment. Reduced intensity conditioning regimens 
have been aimed at both eliminating host-versus-graft 
reactions (graft rejections) and producing major antitu-
mor eﬀ ects. Conversely, nonmyeloablative condition-
ing regimens have relied on optimization of pre- and 
posttransplant immunosuppression to overcome host-
versus-graft reactions, thereby allowing engraftment,16,17
while eradication of tumors has depended nearly exclu-
sively on the graft-versus-tumor eﬀ ects.18 A number of cur-
rently used reduced-intensity or truly nonmyeloablative 
conditioning regimens are shown in Table 1. 
Both reduced-intensity and nonmyeloablative 
regimens are relatively well tolerated.9-15 Two recent 
studies compared transplant-related toxicities after abla-
tive and nonablative conditioning and found that even 
though nonablative recipients were older, more often 
had advanced disease, had more extensive prior therapies 
including failed ablative HCT, and had higher comor-
bidities at HCT, they experienced signiﬁ cantly less grade 
III–IV toxicities after HCT compared to concurrent 
patients given myeloablative conditioning.19,20 In addi-
tion, multivariate analyses adjusting for pretransplant 
factors showed that the rate of 1-year nonrelapse mortal-
ity was lower in nonablative than in ablative recipients.
Graft-Versus-Host Disease and 
Graft-Versus-Tumor Effects after 
Nonmyeloablative Conditioning
Acute graft-versus-host-disease (GVHD), while less fre-
quent than in conventionally transplanted patients,25,26
has remained a signiﬁ cant complication of HCT following 
nonmyeloablative conditioning, and has been associated 
with nonrelapse mortality.25-27 Some reduced-intensity 
conditioning regimens have used in vivo T-cell depletion 
of the grafts (with either antithymocyte globulin [ATG] 
or alemtuzumab [Campath, Berlex]) in order to decrease 
the incidence of acute and chronic GVHD. While these 
strategies achieved their goal, increased incidences of 
infection and disease relapse were observed.28
Th e biology of graft-versus-tumor eﬀ ects remains 
poorly deﬁ ned but is thought to involve reactions to 
polymorphic minor histocompatibility antigens expressed 
either speciﬁ cally on hematopoietic cells or more widely 
on a number of tissue cells.29 Several studies have dem-
onstrated close relationships between GVHD and 
graft-versus-tumor responses after ablative HCT,3-5,7,8,30
although achievement of complete remissions without 
GVHD has been observed in some patients given DLI 
as treatment of leukemic relapse after HCT.7,8,31 Th us, 
even though graft-versus-tumor reactions were thought to 
be obligatory for eradication of underlying malignancies 
after nonmyeloablative conditioning, it seems that clinical 
manifestations of GVHD are not universally required for 
accomplishing remissions. 
In order to address this question, we analyzed data 
from 322 patients given grafts from human leukocyte anti-
gen (HLA)-matched related (n=192) or unrelated (n=130) 
donors after conditioning with 2 Gy TBI with or without 
ﬂ udarabine as well as postgrafting immunosuppression 
with mycophenolate mofetil (MMF) and cyclosporine 
(CSP).18 Multivariate time dependent–regression Cox 
models were used to assess the impacts of either acute 
or chronic GVHD on HCT outcomes. Two hundred 
twenty-one patients had measurable malignant disease 
before HCT, and 98 of them achieved complete remission 
27–963 days after HCT. Acute GVHD of any grade was 
not associated with an increased probability of achieving a 
complete remission, while extensive chronic GVHD was 
suggestively associated with a higher probability of achiev-
ing complete remission (P=.07). Grades II and III–IV acute 
GVHD had no signiﬁ cant impact on relapse/progression, 
but were associated with an increased risk of nonrelapse 
mortality, which resulted in decreased progression-free 
survival. In contrast, extensive chronic GVHD was associ-
ated with a decreased risk of relapse/progression (P=.006) 
and better progression-free survival (P=.003).
Results in Specific Diseases
Acute Myeloid Leukemia and 
Myelodysplastic Syndrome
Th e prognosis for acute myeloid leukemia (AML) in 
patients older than 55 years of age is known to be poor, 
with 2-year probabilities of overall survival of 18% and 
13% for patients 56–64 years old and 65 and older, 
respectively.32 Th is ﬁ nding has led several groups of 
investigators to study the eﬃ  cacy of nonmyeloablative 
HCT as treatment for AML in patients older than 
55–60 years of age12,33-36 (Figure 1).
Sayer and colleagues reported on data from 
113 patients with AML who received HCT after various 
nonmyeloablative or reduced-intensity conditioning 
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* Days posttransplant. 
† Before donor lymphocyte infusions given in 36 of 88 (41%) patients.
‡ In patients with low-grade NHL. 
§ In patients with high-grade NHL.
¶ Grades I–IV. 
# Extensive chronic GVHD.
A = alemtuzumab; ATG = antithymocyte globulin; B = busulfan; C = cyclophosphamide; Cl = cladribine; CSP = cyclosporine; DFS = disease-free survival; 
DLI = donor lymphocyte infusions; F = fludarabine; FK506 = tacrolimus; GVHD = graft-versus-host disease; HLA = human leukocyte antigen; M = melphalan; 
MMF = mycophenolate mofetil; MRD = HLA-matched related donor; MTX = methotrexate; NHL = non-Hodgkin lymphoma; NR = not reported; 
NRM = nonrelapse mortality; OS = overall survival; PFS = progression-free survival; po = orally; R = rituximab; TBI = total body irradiation; 
URD = HLA-matched unrelated donor.
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regimens at multiple centers in Germany.34 Th irty-seven 
percent of the patients were in ﬁ rst (22%), second (11%), 
or third or more (4%) complete remission at the time of 
HCT (Table 2). With a median follow-up of 12 months, 
the 2-year probabilities of overall and progression-free 
survival were 32% and 29%, respectively. In multivariate 
analysis, more than 5% blasts in the marrow at the time of 
HCT, alternative donors, and low Karnofsky performance 
scores were independent adverse prognostic factors for 
progression-free survival.
Hallemeier and coworkers studied 32 consecutive 
patients (median age 47 years) given unrelated marrow 
after 5.5 Gy TBI (given at 30 cGy/min) and cyclophos-
phamide (120 mg/kg) as treatment for AML in ﬁ rst 
(n=15), second (n=15), or third (n=2) complete remis-
sions.12 GVHD prophylaxis consisted of CSP, methotrex-
ate and steroids. Th e 3-year probabilities of overall and 
progression-free survival were 55% and 57%, respectively, 
for patients in ﬁ rst complete remission versus 39% each 
for patients with more advanced disease (Table 2).
Niederwieser and associates reported data from 
122 patients ineligible for conventional HCT given 
allogeneic HCT after conditioning with 2 Gy TBI with 
or without added ﬂ udarabine.35 Postgrafting immuno-
suppression consisted of MMF and CSP. Disease status at 
HCT was ﬁ rst complete remission in 51 patients (42%), 
second complete remission in 39 (32%), and beyond 
second remission in 32 (26%). Two-year probabilities 
of overall survival were 45% for patients for patients 
transplanted in ﬁ rst complete remission, 51% for those 
transplanted in second remission, and 25% for those 
transplanted beyond second remission (Table 2). Low or 
standard cytogenetic risks predicted for better overall sur-
vival versus high cytogenetic risks (P=.009). Th e results 
have encouraged phase III studies investigating the role of 
low-intensity conditioning and allogeneic HCT as treat-
ment for patients older than 55 years of age with AML in 
ﬁ rst complete remission.
Since allogeneic HCT has been the only curative 
treatment for MDS,37 it is not surprising that several 
reports address the eﬃ  cacy of nonablative HCT for MDS. 
Ho and associates reported results in 62 MDS patients 
(median age 56 years) given allografts from related (n=24) 
or unrelated (n=38) donors after reduced-intensity con-
ditioning with ﬂ udarabine (150 mg/m2), oral busulfan 
(8 mg/kg), and alemtuzumab (a humanized monoclonal 
antibody recognizing CD52 antigen expressed on T cells 
and B cells, given at 100 mg total dose).38 Postgrafting 
immunosuppression consisted of CSP alone. Of the 
62 patients, 16 had refractory anemia, 19 had refractory 
anemia with excess blasts, 23 had secondary AML, and 
4 had chronic myelomonocytic leukemia. Th e 1-year 
probabilities of nonrelapse mortality, overall survival, 
and progression-free survival were 5%, 73%, and 61%, 
respectively, for patients given grafts from related donors, 
and 21%, 71%, and 59%, respectively, for patients given 
grafts from unrelated donors. Twenty-six patients required 
DLI, given 126–1323 days after HCT, for cytogenetic 
(n=4) or morphologic relapse (n=6), or for decreased 
donor marrow chimerism (n=16). All patients given DLI 
for cytogenetic relapse but no patients given DLI for 
morphologic relapse responded, while 14 of 16 patients 
given DLI for decreasing marrow chimerism achieved 
full donor-marrow chimerism. Th e 2-year cumulative 
incidences (including patients given DLI) of grade III–IV 
acute GVHD were 17% and 23% for patients given grafts 
from related or unrelated donors, respectively.
Kroger and colleagues39 reported results from 37 MDS 
patients (median age 55 years) given grafts from related 
(n=19) or unrelated (n=18) donors after conditioning with 
ﬂ udarabine (120–180 mg/m2), busulfan (8 mg/kg orally 
or 6.4 mg/kg intravenously), and ATG (n=25). GVHD 
prophylaxis combined CSP with methotrexate or MMF. 
Diagnoses at transplantation were refractory anemia 
(n=8), refractory anemia with excess blasts (n=6), refrac-
tory anemia with excess blasts in transformation (n=13), 
chronic myelomonocytic leukemia (n=3), and secondary 
AML (n=7). Grade II–IV acute GVHD was seen in 37% 
of patients, and chronic GVHD in 48%. Nonrelapse 
mortality was 12% in patients given grafts from related 
donors versus 45% in patients given grafts from unrelated 
Figure 1. Overall and progression-free survival in patients 
56–73 (median 60) years of age with de novo (n=9) or second-
ary (n=4) acute myeloid leukemia in first complete remission 
given allogeneic granulocyte colony-stimulating factor–mobi-
lized peripheral blood mononuclear cells from related donors 
after 2 Gy total body irradiation with (n=5) or without (n=8) 
fludarabine (90 mg/m2). 
Reprinted with permission from Feinstein LC, et al.33 
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Table 2. Results After Nonmyeloablative HCT in Acute Myeloid Leukemia
Niederwieser et al35 Hallemeier et al12 Sayer et al34
N 122 32 113
Median age, yr (range) 57.5 (17–74) 47 (32–60) 51 (16–67)
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Grade II–IV acute GVHD, % 39 19 42
Chronic GVHD, % 42 76 33
NRM, % 19 28 53
OS
45% at 2 yr (CR#1)
51% at 2 yr (CR#2)
25% at 2 yr (>CR#2)
55% at 3 yr (CR#1)
39% at 3 yr (CR#2+)
32% at 2 yr (all pts)
DFS/PFS 36% at 2 yr (all pts)
57% at 3 yr (CR#1)
39% at 3 yr (>CR#2)
29% at 2 yr (all pts)
52% at 2 yr (CR#1)
Median follow-up, mo 23 26 12
CR#1 = first complete remission; CR#2 = second complete remission; >CR#2 = third or more complete remission; CSP = cyclosporine; 
DFS = disease-free survival; G-PBMC = granulocyte colony-stimulating factor–mobilized peripheral blood mononuclear cells; GVHD = graft-
versus-host disease; HCT = hematopoietic cell transplantation; MMF = mycophenolate mofetil; MTX = methotrexate; NRM = nonrelapse 
mortality; OS = overall survival; PFS = progression-free survival; TBI = total body irradiation.
donors. Th e 3-year probabilities of overall and progres-
sion-free survival were 39% and 38%, respectively. 
De Lima and coworkers compared HCT outcomes of 
94 patients given allogeneic HCT after nonmyeloablative 
(ﬂ udarabine [120 mg/m2], cytarabine [4 g/m2], and 
idarubicin [36 mg/m2]) or reduced-intensity (ﬂ udarabine 
[100–150 mg/m2] and melphalan [140 or 180 mg/m2]) 
conditioning.36 Th e 3-year probabilities of overall survival 
were 30% in the nonablative group and 35% in the 
ﬂ udarabine/melphalan group (diﬀ erence between groups 
not signiﬁ cant [NS]). Th e nonablative patients had fewer 
treatment-related complications, a lower incidence of 
grade III–IV acute GVHD (11% vs 19%, NS), a lower 
nonrelapse mortality (16% vs 39%, P=.036), and a higher 
risk of relapse (53% vs 26%, P=.029) than patients given 
ﬂ udarabine plus melphalan. However, these diﬀ erences 
could not simply be explained by diﬀ erences in the inten-
sity of the conditioning, since nonablative recipients were 
mainly given bone marrow from related donors while 
ﬂ udarabine/melphalan patients mainly received granu-
locyte colony-stimulating factor–mobilized peripheral 
blood mononuclear cells (G-PBMC) from unrelated 
donors, which could have impacted both the GVHD 
incidence and graft-versus-tumor eﬀ ects. In addition, 
20% of patients in the nonablative group experienced 
graft rejection, and most of the remainder had mixed 
chimerism, most likely accounting for the reduced graft-
versus-tumor eﬀ ects.18,40
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Scott and associates recently compared the eﬃ  cacy 
of HCT after myeloablative conditioning with busulfan 
(targeted 800–900 ng/mL; starting dose 1 mg/kg every 
6 hours for 16 doses) and cyclophosphamide (120 mg/kg, 
n=132) or nonmyeloablative conditioning with 2 Gy TBI 
and ﬂ udarabine (90 mg/m2, n=40) in MDS patients over 
40 years of age.41 Th e World Health Organization clas-
siﬁ cation (highest at any time before HCT) was refractory 
anemia with or without ringed sideroblasts in 37% of the 
ablative and 22% of the nonablative recipients, refractory 
anemia with excess blasts in 29% of the ablative and 22% 
of the nonablative recipients, and transformed AML in 
34% of the ablative and 55% of the nonablative recipi-
ents. Th e 3-year probabilities of progression-free survival 
were 42% in ablative recipients and 32% in nonablative 
recipients. In multivariate analyses, there were no signiﬁ -
cant diﬀ erences in overall survival (hazard ratio [HR] 1.0, 
P=.89), progression-free survival (HR 0.7, P=.10), and 
relapse risk (HR 1.0, P=.95) between the groups, suggest-
ing that graft-versus-tumor eﬀ ects were more important 
than conditioning intensity in preventing relapse in 
patients with MDS. 
Prospective randomized studies in younger patients 
with MDS are needed to determine the importance of 
conditioning intensity.
Acute Lymphoblastic Leukemia
Allogeneic HCT following myeloablative conditioning 
has been a valid treatment for adult patients with acute 
lymphoblastic leukemia (ALL);42 however, several groups 
of investigators have recently assessed the eﬃ  cacy of 
nonmyeloablative HCT in ALL patients ineligible for 
conventional HCT. Martino and associates summarized 
data from 27 patients (median age 50 years) included in 
4 studies.43 At HCT, 15 patients were in complete remis-
sions, and 12 patients had refractory disease. Conditioning 
regimens consisted of ﬂ udarabine (90–150 mg/m2), plus 
an alkylating agent (melphalan 140 mg/m2 or thiotepa 
10 mg/kg) or 2 Gy TBI. Grade II–IV acute GVHD was 
seen in 48% of patients, and chronic GVHD in 72%. 
Th e 2-year incidences of nonrelapse mortality and overall 
survival were 23% and 31%, respectively. Interestingly, 
GVHD (either acute or chronic) was associated with 
reduced risks of relapse (P=.05) in time-dependent analy-
ses, demonstrating potent graft-versus-ALL eﬀ ects, as has 
been previously observed in patients given grafts after 
myeloablative conditioning.44
Chronic Myeloid Leukemia
Despite promising results with imatinib mesylate (Gleevec, 
Novartis),45 allogeneic HCT has remained the only proven 
curative therapy for chronic myeloid leukemia (CML).46,47
Graft-versus-tumor eﬀ ects have been well documented 
for CML, as evidenced by the ability of DLI to induce 
durable complete remissions in most patients who have 
relapsed after allogeneic HCT, making this disease an ideal 
candidate for HCT following nonablative or reduced-
intensity conditioning.31
Sloand and coworkers described results in 12 patients 
(median age 43 years) given G-PBMC from HLA-iden-
tical siblings after conditioning with cyclophosphamide 
(120 mg/kg) and ﬂ udarabine (125 mg/m2).48 Postgrafting 
immunosuppression consisted of CSP with or without 
MMF. Seven patients were in ﬁ rst chronic phase and 5 in 
second chronic phase at HCT. No patient died of non-
relapse causes. Six patients developed grade II–IV acute 
GVHD, and chronic GVHD was seen in 6 patients. All 
7 patients transplanted in ﬁ rst chronic phase achieved 
stable molecular remissions: 2 with no posttransplant 
intervention; 3 after DLI, imatinib, and interferon; and 
2 after subsequent myeloablative HCT. Four of 5 patients 
transplanted in second chronic phase died in blast cri-
sis and 1 survived in molecular remission. Th e authors 
speculated that the poor disease control might have been 
due to the high leukemic burden in these patients.
Or et al reported results of allogeneic HCT after 
reduced-intensity conditioning combining ﬂ udarabine, 
busulfan, and ATG in 24 relatively young patients (median 
age 35 years) with CML in ﬁ rst chronic phase.23 Nineteen 
patients received grafts from HLA-matched family mem-
bers, and 5 received grafts from HLA-matched unrelated 
donors. Th e 5-year probability of progression-free survival 
was 85%. Th e better results compared with those reported 
by Sloand and coworkers might have been due to a more 
intense conditioning regimen and younger patient ages.
Kerbauy and associates analyzed data from 
24 patients (median age 58 years) with CML in ﬁ rst 
chronic phase (n=14) or beyond (n=10) given G-PBMC 
from HLA-matched related donors after conditioning 
with 2 Gy TBI with (n=16) or without (n=8) ﬂ udarabine 
(90 mg/m2).49 Postgrafting immunosuppression consisted 
of MMF and CSP. Reasons for nonmyeloablative HCT in 
patients younger than 50 years of age (n=7) were diabetes 
mellitus with end-organ damage (n=4), chronic hepatitis 
(n=2), and pulmonary aspergillosis with right-lobe resec-
tion (n=1). Grade II–IV acute GVHD occurred in 50% 
of patients, and extensive chronic GVHD was seen in 
32% of patients. Four of 8 patients not given ﬂ udarabine 
experienced nonfatal graft rejection and recurrence of 
CML, while the 20 remaining patients had sustained 
engraftment. Th e 2-year overall survival rates for patients 
either transplanted in ﬁ rst chronic phase or with more 
advanced CML were 70% and 56%, respectively. Nine 
of 10 patients transplanted in ﬁ rst chronic phase after 
conditioning with 2 Gy TBI and ﬂ udarabine achieved 
molecular remissions 3–24 months after HCT.
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We recently reported the data50 from 21 patients 
with CML in either ﬁ rst chronic phase (n=12) or beyond 
ﬁ rst chronic phase (n=9) given either marrow (n=4) or G-
PBMC (n=17) from HLA-matched unrelated donors after 
conditioning with 2 Gy TBI and ﬂ udarabine (90 mg/m2), 
and postgrafting immunosuppression with MMF and 
CSP. Th e median patient age was 54 years. Reasons for 
nonmyeloablative HCT in patients younger than 50 years 
(n=4) were prior high-dose HCT (n=2), arteriovenous 
malformation (n=1), and morbid obesity (n=1). Sustained 
engraftment was achieved in 5 of 12 patients transplanted 
in ﬁ rst chronic phase, and 6 of 8 patients transplanted 
beyond ﬁ rst chronic phase, while 9 patients rejected their 
grafts 28–400 days after HCT. One patient transplanted 
in second blastic phase died before chimerism evaluation. 
Graft rejections were nonfatal in all cases and followed by 
autologous reconstitution with persistence/recurrence of 
CML. Seven of 11 patients with sustained engraftment, 
including all 5 patients in ﬁ rst chronic phase were alive 
in complete cytogenetic remissions 118–1,205 (median 
867) days after HCT (Figure 2). Two of the remaining 
4 patients with sustained engraftment died of nonrelapse 
causes in complete (n=1) or major (n=1) cytogenetic 
remissions, and 2 died of progressive disease. 
A high rate of graft rejection among CML patients 
receiving grafts from unrelated donors after reduced-
intensity conditioning has also been reported by other 
investigators. A graft failure rate of 44% (3 of 8 patients) 
was described after a regimen that combined ﬂ udarabine 
(150 mg/m2), intravenous busulfan (6.6 mg/kg), and 
ATG.51 Recently, Hallemeier observed graft failure in 
5 of 22 evaluable patients given unrelated grafts after 
conditioning with 5.5 Gy TBI (given as a single dose at 
30 cGy/min) and cyclophosphamide (120 mg/kg).52 Fur-
ther eﬀ orts for reducing the risk of graft rejection in CML 
patients given unrelated HCT are directed at increasing 
the degree of pretransplant immunosuppression.
Chronic Lymphocytic Leukemia
Th e median survival of relatively young patients (<56 years) 
with chronic lymphocytic leukemia (CLL) refractory to 
ﬂ udarabine has been reported to be 48 weeks,53 with only 
10–33% of patients responding to chemotherapy53 or 
alemtuzumab.54 Th ose patients are candidates for therapy 
with allogeneic HCT.
Dreger and coworkers reported results of 77 
CLL patients given reduced-intensity (n=34) or 
nonmyeloablative conditioning (n=43) in European 
Group for Bone and Marrow Transplant (EBMT)-aﬃ  li-
ated centers.55 Median patient age was 54 years with a 
median of 3 previous chemotherapy regimens. Eight 
patients were in complete remission, 42 in partial remis-
sion, and 27 had refractory disease at transplant. Th e 
1-year nonrelapse mortality was 18%, and the 2-year 
probabilities of overall and progression-free survival were 
72% and 56%, respectively. 
Schetelig and associates analyzed data from 30 CLL 
patients (median age 50 years) given grafts from related 
(n=15) or unrelated (n=15) donors after conditioning 
with ﬂ udarabine (180 mg/m2), busulfan (8 mg/kg), 
and ATG.56 GVHD prophylaxis consisted of CSP given 
alone (n=7), or in combination with MMF (n=12) or 
methotrexate (n=11) (Table 3). At HCT, 14 patients 
(46%) had chemorefractory disease, including 10 patients 
(33%) who were refractory to ﬂ udarabine. Twenty-ﬁ ve 
percent of patients achieved complete remission at 1 year 
and 66% at 2 years after HCT. Th e 2-year probabilities 
of nonrelapse mortality, overall survival, and progression-
free survival were 15%, 72%, and 67%, respectively.
Khouri and associates reported data from 17 CLL 
patients (median age 54 years) given G-PBMC (n=16) 
or marrow (n=1) from HLA-matched related donors 
after conditioning with ﬂ udarabine (90 mg/m2) and 
cyclophosphamide (2,250 mg/m2), with subsequent 
incorporation of rituximab (Rituxan, Genentech) in 
the regimen to enhance tumor control after the initial 
7 patients.57 GVHD prophylaxis consisted of tacrolimus 
and methotrexate. All patients were either refractory 
to ﬂ udarabine or had relapsed following ﬂ udarabine 
therapy. Ten patients with persistent disease after HCT 
received DLI with or without rituximab after tacrolimus 
discontinuation in order to increase graft-versus-tumor 
eﬀ ects. Sixteen patients ultimately achieved complete 
(n=12) or partial (n=4) remissions. Th e 2-year prob-
abilities of nonrelapse mortality, overall survival, and 
Figure 2. Evolution of BCR/ABL mRNA in 4 patients with 
first chronic phase chronic myeloid leukemia and 1 patient 
with accelerated phase chronic myeloid leukemia given unre-
lated grafts after 2 Gy total body irradiation and fludarabine. 
Molecular remissions were achieved 84–524 (median 230) days 
after hematopoietic cell transplantation. 
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progression-free survival were 22%, 80%, and 60%, 
respectively (Table 3). 
Sorror and colleagues described outcomes in 64 CLL 
patients (median age 56 years) who received HCT 
from HLA-matched related (n=44) or unrelated (n=20) 
donors after conditioning with 2 Gy TBI alone (n=11) 
or combined with ﬂ udarabine (90 mg/m2, n=53).58
Postgrafting immunosuppression consisted of MMF and 
CSP. Ninety-ﬁ ve percent of patients were refractory to 
at least 1 regimen, including 88% who were refractory 
to ﬂ udarabine. Th ree patients experienced graft rejec-
tion. One of the 3 died of aplasia and the 2 others were 
surviving with autologous marrow recovery and progres-
sive disease. With a median follow-up of 24 months, the 
overall response rate was 67% (50% complete remission). 
Estimated 2-year rates of nonrelapse mortality, overall 
survival, and progression-free survival were 22%, 60%, 
and 52%, respectively (Table 3 and Figure 3).
Taken together, these results suggest that CLL is 
remarkably susceptible to graft-versus-tumor eﬀ ects, and 
that HCT after nonmyeloablative or reduced-intensity 
conditioning should be explored in phase III studies in 
patients with ﬂ udarabine-refractory CLL. 
Lymphoma
Conventional allogeneic HCT is a potential curative treat-
ment for patients with non-Hodgkin lymphoma (NHL) 
in whom nontransplant therapies have failed.59 Th e ben-
eﬁ ts of allogeneic HCT have been attributed to both the 
intensities of the conditioning regimens used and graft-
versus-lymphoma eﬀ ects.60 However, the use of con-
ventional allogeneic HCT has been associated with 
high nonrelapse mortalities (up to 40%) that are even 
higher (50–85%) in patients who had failed autologous 
HCT.61 Th is high rate of mortality has led to the use of 
nonmyeloablative or reduced-intensity conditioning 
before HCT in patients with NHL who have failed lym-
phoma therapy and who are ineligible for conventional 
allogeneic HCT because of age and comorbid conditions.
Registry Data Study: Robinson and colleagues 
reported results in 188 patients with lymphoma (low-
grade NHL [n=52], high-grade NHL [n=62], Hodgkin 
disease [n=52], and mantle-cell lymphoma [n=22]) given 
HCT after various reduced-intensity or nonmyeloablative 
conditioning regimens in EBMT-aﬃ  liated centers.62
Median age was 40 years, and the median number of 
prior treatments was 3 courses. Forty-eight percent of 
patients had failed autologous transplantation, and 21% 
had chemoresistant disease. Th e overall 1-year probability 
of nonrelapse mortality was 26%, and that incidence was 
signiﬁ cantly higher in patients older than 50 years (39% 
vs 22% in younger patients, P=.03). Twenty-two patients 
received DLI with (n=8) or without (n=14) preceding 
chemotherapy for either disease progression or persis-
tence after HCT. Ten of the 14 patients given DLI alone 
achieved complete (n=6) or partial (n=4) remissions. Th e 
2-year overall and progression-free survival probabilities 
were 65% and 54%, respectively, for patients with low-
grade NHL, 47% and 13%, respectively, for patients with 
high-grade NHL, 13% and 0%, respectively, for patients 
with mantle-cell lymphoma, and 56% and 42%, respec-
tively, for patients with Hodgkin disease. In multivariate 
analyses, chemosensitive disease at HCT was associated 
with longer overall (relative risk [RR], 2.4; P=.002) and 
progression-free (RR, 2.3; P=.007) survival. 
Low-grade NHL: Khouri and associates reported 
data from 20 patients with low-grade NHL given 
grafts from siblings after conditioning with ﬂ udarabine 
(90–125 mg/m2) and cyclophosphamide (2,000–
2,250 mg/m2), with or without added rituximab.24 Post-
grafting immunosuppression consisted of tacrolimus and 
methotrexate. All patients had chemosensitive disease at 
HCT, including 12 patients (60%) who were in complete 
remission. Grade II–IV acute GVHD occurred in 20% 
of patients while extensive chronic GVHD was seen in 
64% of patients. None have had relapse of disease after a 
median follow-up of 21 months. Th e 2-year probability 
of being alive in complete remission was 84%. 
Morris and colleagues reported results of 41 patients 
with low-grade lymphoproliferative disorders given 
allogeneic HCT after conditioning with ﬂ udarabine 
(150 mg/m2), melphalan (140 mg/m2) and alemtuzumab 
(100 mg).22 Forty patients (98%) had chemosensitive 
disease at HCT, including 11 patients (27%) who were 
in complete remission. Th e 3-year probability of relapse 
was 44% (some of the relapsing patients responded to 
discontinuation of immunosuppression or to DLI). Th e 3-
year probabilities of overall survival were 78% for patients 
given grafts from related donors and 56% for those with 
grafts from unrelated donors.63 Th e 2-year incidence of 
nonrelapse mortality was remarkably low (11%).
Mantle-Cell Lymphoma: Khouri and coworkers 
analyzed data from a total of 18 patients treated on 2 
consecutive trials.64 Five patients received HCT after 
conditioning with cisplatinum (100 mg/m2), ﬂ udarabine 
(60 mg/m2) and cytarabine (2 g/m2), and 13 received 
HCT after conditioning with ﬂ udarabine (90 mg/m2), 
cyclophosphamide (2,250 mg/m2), and rituximab. 
Tacrolimus and methotrexate were used as postgrafting 
immunosuppression. Five patients had failed autologous 
HCT and 16 (89%) had chemosensitive disease includ-
ing 8 patients who were in complete remission at HCT. 
Fourteen patients received grafts from related donors 
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Schetelig et al56 Khouri et al57 Sorror et al58
N 30 17 64
Median age, yr (range) 50 (12–63) 54 (43–73) 56 (44–69)
Disease status at HCT, n (%)
CR:  Yes
No











Fludarabine (180 mg/m²), 
busulfan (8 mg/kg) and 
ATG
Fludarabine 
(90 mg/m²), cyclophosphamide 
(2250 mg/m²), +/-rituximab
2 Gy TBI +/- ﬂ udarabine 
(90 mg/m²)



















Grade II–IV acute GVHD, % 56 29 55%
Chronic GVHD, % 75 60 50%
NRM 15% at 2 yr 22% at 2 yr 22% at 2 yr
Response rate 93% (40% CR) 94% (70% CR) 67% (50% CR)
OS 72% at 2 yr 80% at 2 yr 60% at 2 yr
DFS/PFS 67% at 2 yr 60% at 2 yr* 52% at 2 yr
Median follow-up, mo (range) 24 (7–43) 21 (11–84) 24 (3–63)
* Current PFS. 
ATG = antithymocyte globulins; CR = complete remission; CSP = cyclosporine; DFS = disease-free survival; G-PBMC = granulocyte colony-stimulating factor–
mobilized peripheral blood mononuclear cells; GVHD = graft-versus-tumor disease; HCT = hematopoietic cell transplantation; NR = not reported; NRM = nonrelapse 
mortality; MMF = mycophenolate mofetil; MTX = methotrexate; OS = overall survival; PFS = progression-free survival; TBI = total body irradiation.
Table 3. Results After Nonmyeloablative HCT in Chronic Lymphocytic Leukemia
and 4 from unrelated donors. Grade II–IV acute GVHD 
occurred in 17% of patients and chronic GVHD in 36%. 
Complete remissions were maintained in the 8 patients 
transplanted in remission and accomplished in 9 of the 
10 remaining patients. Th ree patients eventually relapsed, 
1 of whom achieved complete remission after DLI. Th ree-
year probabilities of overall and current progression-free 
survival were 86% and 82%, respectively.
Morris and colleagues reported results in 10 patients 
given grafts after ﬂ udarabine (150 mg/m2), melphalan 
(140 mg/m2), and alemtuzumab (100 mg).22 Th e 3-year 
probabilities of relapse and overall survival were 50% and 
60%, respectively. 
Maris and associates reported a multi-institution 
study of 33 patients with relapsed or refractory mantle-
cell lymphoma given allogeneic HCT after 2 Gy TBI 
and ﬂ udarabine (90 mg/m2).65 Postgrafting immunosup-
pression consisted of MMF and CSP. Sixteen patients 
were given grafts from HLA-identical related donors 
and 17 from HLA-matched unrelated donors. Fourteen 
patients had failed autologous HCT and 13 had chemo-
refractory disease. Grade II–IV acute GVHD occurred in 
57% of patients, and extensive chronic GVHD was seen 
in 64%. Complete remissions were maintained in the 13 
patients transplanted in remission and accomplished in 14 
of the 20 remaining patients. Th e 2-year probabilities of 
relapse, nonrelapse mortality, and overall and progression-
free survival were 9%, 24%, 65%, and 60%, respectively 
(Figure 4). 
High-grade NHL: A multicenter UK study using 
conditioning with ﬂ udarabine (150 mg/m2), melphalan 
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(140 mg/m2), and alemtuzumab (100 mg) included 
37 patients with high-grade NHL (including 22 with 
diﬀ use large B-cell lymphoma).59 Th e 3-year probabilities 
of relapse, nonrelapse mortality, and overall and progres-
sion-free survival were 52%, 38%, 34%, and 34%, respec-
tively. Only 1 of 8 patients transplanted with refractory 
disease remained alive without progression at 2.5 years 
after HCT.
Preliminary data from the Seattle consortium multi-
center study were recently analyzed.66 Forty-two patients 
with high-grade NHL were given grafts from related 
(n=29) or unrelated (n=13) donors after conditioning 
with 2 Gy TBI with or without ﬂ udarabine (90 mg/m2). 
Twenty-four patients had failed autologous HCT. Th e 
1-year probabilities of relapse, nonrelapse mortality, and 
overall and progression-free survivals were 36%, 15%, 
63%, and 49%, respectively. Chemorefractory disease 
at HCT was associated with lower overall (HR 0.21, 
P=.0005) and progression-free (HR 0.21; P=.0003) sur-
vival rates, suggesting that tumor chemosensitivity should 
be a major consideration in the selection of patients who 
might beneﬁ t from HCT with nonablative conditioning. 
Hodgkin Disease: Robinson et al67 reported out-
comes among 311 patients (median age 31 years) from 
EBMT-aﬃ  liated centers given allogeneic HCT from 
HLA-matched related (n=221), HLA-matched unrelated 
(n=61), or HLA-mismatched (n=17) donors after various 
reduced-intensity or nonmyeloablative conditioning regi-
mens as treatment for Hodgkin disease. Forty-ﬁ ve percent 
of patients had failed autologous HCT, and 32% had che-
moresistant disease. Th e 100-day and 1-year probabilities 
of nonrelapse mortality were 17% and 24%, respectively, 
and these rates were signiﬁ cantly higher in patients with 
chemoresistant disease at HCT. Th e 2-year probabilities 
of relapse, overall survival, and progression-free survival 
were 64%, 46%, and 26%, respectively. In multivariate 
analyses, chemoresistant disease at HCT was associated 
with decreased overall (P<.0001) and progression-free 
(P<.0001) survival.
Multiple Myeloma
Myeloablative allogeneic HCT is the only proven curative 
treatment for MM.68 Th is eﬃ  cacy has been attributed to 
ablation of myeloma cells both by the intense conditioning 
regimen and by graft-versus-myeloma eﬀ ects, which have 
been directly demonstrated by the ability of DLI to induce 
remissions in some patients who relapsed after allografts.69
However, the very high transplant-related mortality asso-
ciated with standard allogeneic HCT (20–50% in the ﬁ rst 
6 months, even in younger patients) has tempered enthu-
siasm for this approach,70 and has led to the development 
of nonablative HCT for patients with MM.71-73
Figure 3. Evidence of graft-versus-tumor effects in a CLL 
patient with bone marrow involvement (CD20+, CD52+ cells 
with trisomy 12 on fluorescent in situ hybridization analysis) 
and axillary adenopathy at HCT, given G-PBMC from an 
HLA-matched unrelated donor after 2 Gy TBI and fludarabine 
(90 mg/m2).58 The patient achieved a complete remission on 
day 84, showed recurrent marrow disease on day 180, but then 
achieved a remission by day 365 (without treatment) after hav-
ing had extensive chronic GVHD. 
CLL = chronic lymphocyte leukemia; G-PBMC = granulocyte colony-stimulat-
ing factor–mobilized peripheral blood mononuclear cells; GVHD = graft-ver-
sus-host disease; HCT = hematopoietic cell transplantation; HLA = human 
leukocyte antigen; TBI = total body irradiation.
Figure 4. Kaplan-Meier estimates of progression-free survival 
among patients with mantle-cell lymphoma given grafts from 
related (n=16) or unrelated (n=17) donors after 2 Gy TBI with 
or without fludarabine (90 mg/m2). Ten of 17 unrelated recipi-
ents and 4 of 16 sibling recipients had failed autologous HCT. 
Thirty-nine percent of the patients had disease which was re-
fractory to salvage chemotherapy or autologous HCT. 
Reprinted with permission from Maris MB et al.65 © the American Society of 
Hematology.
HCT = hematopoietic cell transplantation; TBI = total body irradiation.
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Badros and associates treated 25 MM patients with 
intermediate dose melphalan (100 mg/m2) followed 
by HCT from HLA-matched siblings.72 Six additional 
patients were given grafts from HLA-matched unrelated 
donors after melphalan (100 mg/m2), 2.5 Gy TBI, and 
ﬂ udarabine (60 mg/m2). All but 1 patient had failed 
autologous HCT, and 21 (68%) had a chromosome 
13 abnormality. Nonrelapse mortality during the ﬁ rst 
100 days was 10%. Overall, 61% of patients achieved 
complete or near-complete remissions. Th e 2-year prob-
abilities of overall and progression-free survival were 31% 
each (Table 4).
Maloney and coworkers analyzed data from 54 MM 
patients who initially received autologous HCT after a 
cytoreductive dose of melphalan (200 mg/m2), followed 
40–229 (median 62) days later by allogeneic HCT after 2 
Gy TBI.73 Patients were 29–71 (median 52) years old, and 
48% had refractory (35%) or relapsed (13%) disease. Th e 
100-day mortality rates after autologous and allogeneic 
HCT were 2% and 2%, respectively. With a median 
follow-up of 552 days after allografting, 57% of patients 
achieved complete remission and 26% partial remission. 
Th e estimated 2-year overall and progression-free survival 
were 78% and 55%, respectively (Table 4).
Kroger and colleagues recently analyzed data from 
120 MM patients (median age 52 years) treated with 
melphalan/ﬂ udarabine followed by allogeneic HCT.74 Th e 
1-year incidence of nonrelapse mortality was 18%, while 
Badros et al72 Maloney et al73 Kroger et al74
N 31 54 120
Median age, yrs (range) 56 (38–69) 52 (29–71) 52 (31–65)














Melphalan 100 mg/m² 
(n=25), melphalan 
100 mg/m², 2.5 Gy TBI, 
ﬂ udarabine (60 mg/m²) (n=6) 
Melphalan 200 mg 
(auto HCT) followed 
40–229 days later by 2 
Gy TBI (allo HCT)
Fludarabine, melphalan 
+/- ATG (various doses)
Tandem auto/allo HCT, n (%) 0 54 (100) 38 (32)



















Grade II–IV acute GVHD 52% 38% 46%
Chronic GVHD 33% 46% 47%
NRM 9/31 pts (29%) 9/54 pts (17%) 18% at 1 yr
Response rate 61% CR/nCR 83% (57% CR) 87% (49% CR)
OS 31% at 2 yr 78% at 2 yr 59% at 2 yr
DFS/PFS 31% at 2 yr 55% at 2 yr 39% at 2 yr
Median follow-up, mo (range) 6 (1.5–24) 20 (8–40) 16 (3–46)
allo = allogeneic; ATG = antithymocyte globulins; auto = autogeneic; CR = complete remission; CSP = cyclosporine; DFS = disease-free survival; G-PBMC = granulo-
cyte colony-stimulating factor–mobilized peripheral blood mononuclear cells; GVHD = graft-versus-host disease; HCT = hematopoietic cell transplantation; 
MMF = mycophenolate mofetil; nCR = near complete remission; NRM = nonrelapse mortality; OS = overall survival; PFS = progression-free survival; 
TBI = total body irradiation.
Table 4. Results After Nonmyeloablative HCT in Multiple Myeloma
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2-year probabilities of relapse, overall survival, and pro-
gression-free survival were 43%, 59%, and 39%, respec-
tively. In multivariate analyses, relapse after autologous 
HCT was the most signiﬁ cant risk factor for nonrelapse 
mortality (HR 2.80; P=.02), relapse (HR 4.14; P<.001), 
failure of progression-free survival (HR 3.11; P<.001), 
and death (HR 2.69; P=.005). Relapse was diminished by 
chronic (but not acute) GVHD in a time-dependent Cox 
model (P=.02).
Metastatic Renal Cell Carcinoma
Childs and associates ﬁ rst demonstrated the eﬃ  cacy of 
graft-versus-tumor eﬀ ects in 1 patient with renal cell 
carcinoma (RCC) in 1999.75 Th e authors next reported 
results in 19 patients with progressive metastatic RCC 
treated with cyclophosphamide and ﬂ udarabine followed 
by allogeneic HCT and posttransplant immunosuppres-
sion with CSP.76 Ten patients (53%) achieved objective 
clinical responses, and 3 (16%) achieved sustained com-
plete remissions. Subsequent reports from other centers 
conﬁ rmed that similar treatment protocols could induce 
objective regressions of metastatic RCC in 8–57% of 
patients studied,77-80 and 1 study suggested that responses 
might be due to CD8(+) T cells recognizing minor his-
tocompatibility antigens on tumor cells.80 Based on these 
encouraging preliminary results, further exploration of 
nonablative HCT for RCC is warranted in the setting of 
clinical trials.
Summary and Possible Current Indications
Reduced-intensity and nonmyeloablative condition-
ing regimens have allowed for sustained engraftment of 
allogeneic hematopoietic cells and the development of 
therapeutic graft-versus-tumor eﬀ ects. Achievement of 
complete remissions might require extended periods of 
time, with some patients achieving complete remissions 
more than 1 year after HCT. In patients with slowly 
progressing diseases such as CLL, low-grade NHL, 
or chronic-phase CML, or those with more aggres-
Potential role Comments
AML Attractive in older patients in CR#1/CR#2.35
Phase III “randomized” trials ongoing in patients 
in CR#1.
ALL Feasible in older patients with ALL in CR.43,82 Few published data.
CML
Particularly attractive in older patients with sibling 
donors.23,49 Results are better in CP#1 than in more 
advanced stages.
Increase immunosuppression before HCT in order 
to assure consistent engraftment in patients given 
grafts from unrelated donors.47
CLL
Nonablative HCT eﬃ  cacious.
Very attractive for patients refractory to ﬂ udarabine.55-58
Phase III trials needed to compare nonablative 
HCT with alemtuzumab or chemotherapy.
Low-grade NHL Nonablative HCT clearly eﬃ  cacious.62
Phase III studies warranted to compare nonabla-
tive HCT with alternative treatment strategies.
MCL
Nonablative HCT clearly eﬃ  cacious.
Very attractive in patients relapsing after autologous 
HCT.64,65
Phase III studies warranted.
High-grade NHL/ 
Hodgkin disease
Eﬃ  cacious in patients with low tumor burden. Increas-
ingly used in patients failing autologous HCT.62
Better results in patients with chemosensitive 
diseases and in patients with low tumor burden.
Consider debulking with autologous HCT 
(tandem auto/allo HCT).
Multiple myeloma
Nonablative HCT eﬀ ective, particularly in patients 
with chemosensitive disease.74
Promising results of tandem allogeneic and autologous 
HCT.73
Ongoing phase III studies assess the role of 
tandem autologous/allogeneic HCT.
Solid tumors
Graft-versus-RCC eﬀ ect has been observed in selected 
patients.76
Ongoing phase II studies.
ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; CLL = chronic lymphocytic leukemia; CML = chronic myeloid leukemia; 
CP1 = first chronic phase; CR#1 = first complete remission; CR#2 = second complete remission; HCT = hematopoietic cell transplantation; 
MCL = mantle-cell lymphoma; NHL = non-Hodgkin lymphoma; RCC = renal cell carcinoma.
Table 5. Potential Current Roles of HCT After Nonmyeloablative or Reduced-Intensity Conditioning
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sive diseases in complete remission, nonmyeloablative 
conditioning might be suﬃ  cient to achieve cures of the 
underlying diseases (Table 5). In patients with aggressive 
diseases such as acute leukemias, MM, high-grade NHL, 
or Hodgkin disease who were not in complete remission, 
cytoreduction by preceding chemotherapy or autologous 
HCT might be required, and results have been worst in 
those patients with chemorefractory diseases. Remaining 
challenges include prevention of both severe GVHD and 
infections and increasing the eﬃ  cacy of graft-versus-tumor 
eﬀ ects. Further progress in adoptive transfer of T-cell 
populations with relative tumor speciﬁ city81 and combi-
nations of nonablative HCT with targeted therapies such 
as imatinib, rituximab, or radiolabeled monoclonal anti-
bodies might make the use of nonmyeloablative allogeneic 
HCT eﬀ ective even in patients with large disease burden.
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